Sunshine Biopharma Files 8-K on Shareholder Matters
Ticker: SBFMW · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma Inc. (SBFMW) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
Sunshine Biopharma filed an 8-K on Dec 10th about shareholder votes. Keep an eye on what they're voting on.
AI Summary
Sunshine Biopharma Inc. filed an 8-K on December 10, 2024, reporting on matters submitted to a vote of security holders. The filing details the company's corporate structure, including its incorporation in Colorado and its fiscal year end of December 31. It also lists its business and mailing addresses in Fort Lauderdale, Florida.
Why It Matters
This filing indicates that Sunshine Biopharma Inc. is engaging in corporate actions requiring shareholder approval, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing a vote of security holders, not an event that inherently introduces new financial risk.
Key Numbers
- 001-41282 — SEC File Number (Identifies the company's filing history with the SEC.)
- 20-5566275 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Sunshine Biopharma Inc. (company) — Registrant
- December 10, 2024 (date) — Date of Report
- Colorado (jurisdiction) — State of Incorporation
- Fort Lauderdale, Florida (location) — Business Address
FAQ
What specific matters were submitted to a vote of Sunshine Biopharma Inc.'s security holders?
The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals in the provided text.
When was the report filed and what is the earliest event date reported?
The report was filed on December 10, 2024, and the earliest event reported is also December 10, 2024.
In which state is Sunshine Biopharma Inc. incorporated?
Sunshine Biopharma Inc. is incorporated in Colorado.
What is the company's business address?
The company's business address is 333 LAS OLAS WAY, CU4 SUITE 433, FORT LAUDERDALE, FL 33301.
What is Sunshine Biopharma Inc.'s fiscal year end?
Sunshine Biopharma Inc.'s fiscal year ends on December 31.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2024-12-10 16:26:24
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Filing Documents
- sunshine_8k.htm (8-K) — 32KB
- 0001683168-24-008607.txt ( ) — 244KB
- sbfm-20241210.xsd (EX-101.SCH) — 3KB
- sbfm-20241210_def.xml (EX-101.DEF) — 26KB
- sbfm-20241210_lab.xml (EX-101.LAB) — 36KB
- sbfm-20241210_pre.xml (EX-101.PRE) — 25KB
- sunshine_8k_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of
Item 5.07 Submission of Matters to a Vote of Security Holders. On December 10, 2024, Sunshine Biopharma Inc. (the "Company") held its annual meeting of stockholders. At the meeting, (i) Dr. Steve N. Slilaty, Dr. Abderrazzak Merzouki, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were each elected as directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified, and (ii) stockholders ratified the board of directors' appointment of Bush & Associates CPA LLC as the Company's independent registered public accounting firm for 2024. The vote on these matters was as follows: 1. Election of Directors: FOR WITHHELD BROKER NON-VOTE Dr. Steve N. Slilaty 130,067,932 48,554 0 Dr. Abderrazzak Merzouki 130,080,510 35,976 0 Dr. Rabi Kiderchah 130,076,086 40,400 0 Mr. David Natan 130,070,417 46,069 0 Dr. Andrew Keller 130,075,596 40,890 0 2 . Ratification of the board of directors' appointment of Bush & Associates CPA LLC as the Company's independent registered public accounting firm for 2024. FOR AGAINST ABSTAIN 130,089,305 15,456 11,725 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 10, 2024 SUNSHINE BIOPHARMA INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3